# Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia

> **NCT03367299** · PHASE2 · COMPLETED · sponsor: **Gruppo Italiano Malattie EMatologiche dell'Adulto** · enrollment: 149 (actual)

## Conditions studied

- Acute Lymphoid Leukemia
- Philadelphia Chromosome-Negative B-Cell Precursor

## Interventions

- **DRUG:** Chemotherapy + Blinatumomab

## Key facts

- **NCT ID:** NCT03367299
- **Lead sponsor:** Gruppo Italiano Malattie EMatologiche dell'Adulto
- **Sponsor class:** OTHER
- **Phase:** PHASE2
- **Study type:** INTERVENTIONAL
- **Status:** COMPLETED
- **Start date:** 2018-06-08
- **Primary completion:** 2024-09-02
- **Final completion:** 2024-09-02
- **Target enrollment:** 149 (ACTUAL)
- **Last updated:** 2025-01-22


## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT03367299

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT03367299, "Sequential Chemotherapy and Blinatumomab to Improve MRD Response and Survival in Acute Lymphoblastic Leukemia". Retrieved via AI Analytics 2026-05-24 from https://api.ai-analytics.org/clinical/NCT03367299. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*